Search results for "Interferon"

showing 10 items of 963 documents

Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy

2009

Treatment with peginterferon alfa and ribavirin produces a sustained virologic response (SVR) in approximately 60% of hepatitis C virus (HCV)-infected patients. Alternate options are needed for patients who relapse or do not respond to therapy.This prospective, international, multicenter, open-label study evaluated efficacy and safety of peginterferon alfa-2b (1.5 microg/kg/wk) plus weight-based ribavirin (800-1400 mg/day) in 2333 chronic HCV-infected patients with significant fibrosis/cirrhosis whose previous interferon alfa/ribavirin therapy failed. Patients with undetectable HCV-RNA at treatment week (TW) 12 received 48 weeks of therapy; patients with detectable HCV-RNA at TW12 could ent…

Malemedicine.medical_specialtyHepatitis C virusPeginterferon-alfaHepacivirusInterferon alpha-2medicine.disease_causeAntiviral AgentsGastroenterologyPolyethylene Glycolschemistry.chemical_compoundPharmacotherapyInternal medicineRibavirinmedicineHCV ANTIVIRAL THERAPYHumansTreatment FailureInterferon alfaHepatologybusiness.industryRibavirinGastroenterologyInterferon-alphavirus diseasesHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant Proteinsdigestive system diseaseschemistryImmunologyRNA ViralPeginterferon alfa-2bDrug Therapy CombinationFemalebusinessViral loadmedicine.drug
researchProduct

HCV cirrhosis at the edge of decompensation: Will paritaprevir with ritonavir, ombitasvir, dasabuvir, and ribavirin solve the need for treatment?

2014

BACKGROUND: The interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r) and the NS5A inhibitor ombitasvir (also known as ABT-267) plus the nonnucleoside polymerase inhibitor dasabuvir (also known as ABT-333) and ribavirin has shown efficacy against the hepatitis C virus (HCV) in patients with HCV genotype 1 infection. In this phase 3 trial, we evaluated this regimen in previously untreated patients with HCV genotype 1 infection and no cirrhosis. METHODS: In this multicenter, randomized, double-blind, placebocontrolled trial, we assigned previously untreated patients with HCV genotype 1 infection, in a 3:1 ratio, to an active regimen consisting of a single-ta…

Malemedicine.medical_specialtyMacrocyclic CompoundsDirect-acting antiviralsLiver functionGastroenterologyAntiviral Agents03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePegylated interferonInternal medicineRibavirinmedicineHumansAnilidesPortal hypertensionUracilAdvanced liver diseaseSulfonamidesDasabuvirRitonavirHepatologybusiness.industryRibavirinvirus diseasesHepatitis C ChronicVirologyOmbitasvir3. Good healthRegimenchemistryParitaprevir030220 oncology & carcinogenesis030211 gastroenterology & hepatologyRitonavirFemaleLiver functionCarbamatesbusinessmedicine.drugJournal of Hepatology
researchProduct

Chemoradioimmunotherapy with 5-fluorouracil, cisplatin and interferon-α in pancreatic and periampullary cancer: Results of a feasibility study

2008

Abstract Background Recent studies give rise to the hypothesis, that adjuvant chemoradioimmunotherapy with 5-fluorouracil (5-FU), cisplatin and interferon-α (IFN-α) might be a possible new treatment of pancreatic cancer in resected patients. We report the up-to-now experience at our institution. Patients and methods Eleven patients with histological diagnosis of localized carcinoma of the pancreas ( n  = 7) or periampullary ( n  = 4) were prospectively analyzed. Four patients were deemed unresectable because of local invasion of adjacent organs (neoadjuvant setting) and seven patients underwent curative resection (adjuvant setting). Eight patients were classified as T3 carcinomas and three …

Malemedicine.medical_specialtyPancreatic diseasemedicine.medical_treatmentAntineoplastic AgentsRisk AssessmentGastroenterology03 medical and health sciences0302 clinical medicineInternal medicinePancreatic cancermedicinePeriampullary cancerHumansNeoplasm InvasivenessRadiology Nuclear Medicine and imagingSurvival rateNeoplasm Staging030304 developmental biology0303 health sciencesbusiness.industryPatient SelectionRadiotherapy Dosagemedicine.diseaseCombined Modality Therapypeople.cause_of_deathRecombinant Proteins3. Good healthSurgeryPancreatic NeoplasmsSurvival RateRadiation therapyOncology030220 oncology & carcinogenesisConcomitantInterferon Type IFeasibility StudiesFemaleFluorouracilImmunotherapyCisplatinbusinesspeopleChemoradiotherapyProgressive diseaseCancer/Radiothérapie
researchProduct

Clinical significance of abdominal lymphadenopathy in chronic liver disease

2002

Abstract The possibility of assessing the relationship of ultrasound (US)-detected abdominal lymphadenopathy with etiology, biochemical findings, and histologic data in patients with chronic liver disease was evaluated. US examination of the upper abdomen was performed in 321 consecutive patients with various chronic liver disorders and 56 control patients. The prevalence of lymphadenopathy in chronic liver disease was 38%. This prevalence varied according to etiology of liver disease, from 50% in chronic hepatitis C virus (HCV) to less than 10% in alcoholicc cirrhosis and hepatitis B-virus (HBV)-related chronic liver disease. Patients with lymphadenopathy showed significantly higher serum …

Malemedicine.medical_specialtyPathologyCirrhosisAcoustics and UltrasonicsHepatitis C virusBiophysicsAntineoplastic Agentsmedicine.disease_causeChronic liver diseaseGastroenterologyLiver diseaseInternal medicineAbdomenmedicineHumansRadiology Nuclear Medicine and imagingProspective StudiesLymphatic DiseasesUltrasonographyHepatitis B virusHepatitisAnalysis of VarianceRadiological and Ultrasound Technologymedicine.diagnostic_testbusiness.industryLiver DiseasesInterferon-alphaMiddle Agedmedicine.diseasemedicine.anatomical_structureLiverLiver biopsyChronic DiseaseAbdomenFemaleLymph NodesbusinessUltrasound in Medicine & Biology
researchProduct

The chemiluminescence activity of peripheral blood mononuclear cells during acute experimental allergic encephalomyelitis

1987

The spontaneous chemiluminescence activity (CL-A) of peripheral mononuclear cells (MNC) was examined in Lewis rats with acute experimental allergic encephalomyelitis (EAE), compared to rats immunized with complete adjuvant (n = 11) and healthy animals (n = 16). In rats with EAE, CL-A increased sharply 8-9 days after immunization (3420 +/- 3124 counts/10 s, n = 16) at the time of flattening of the weight curve. This CL-A peak was compared to that of animals immunized with complete adjuvant: 765 +/- 441 counts/10 s (P = 0.01) and healthy rats: 450 +/- 172 counts/10 s (P = 0.0001). After this initial peak in EAE rats, CL-A decreased almost to normal values when animals lost weight (746 +/- 251…

Malemedicine.medical_specialtyPathologyEncephalomyelitis Autoimmune ExperimentalEncephalomyelitisImmunologyCentral nervous systemPeripheral blood mononuclear cellInterferon-gammaImmunopathologyInternal medicineParalysismedicineAnimalsImmunology and AllergyLymphocytesbusiness.industryBrainmedicine.diseaseRatsRespiratory burstPeripheralEndocrinologymedicine.anatomical_structureNeurologyRats Inbred LewAcute DiseaseLuminescent MeasurementsLeukocytes MononuclearNeurology (clinical)medicine.symptombusinessInfiltration (medical)Journal of Neuroimmunology
researchProduct

Assessment of hepatitis C virus-RNA clearance under combination therapy for hepatitis C virus genotype 1: performance of transcription-mediated ampli…

2007

Monitoring of HCV-RNA in blood during antiviral therapy is performed mostly by commercially available reverse transcription polymerase chain reaction-based (RT-PCR) assays, with a lower detection limit of 30-50 IU/mL of HCV-RNA. Use of different tests in the pivotal trials of combination therapy has generated some discordance, in terms of predictive value of the early virological response (EVR). To evaluate whether the use of a more sensitive test, as a qualitative assay based on transcription mediated amplification (TMA) with a lower detection limit of 5-10 IU/mL of HCV-RNA, may obtain a better prediction of EVR and of the ultimate virological outcome, we retrospectively evaluated serial s…

Malemedicine.medical_specialtySettore MED/07 - Microbiologia E Microbiologia ClinicaSettore MED/09 - Medicina InternaCombination therapyGenotypeTranscription GeneticTranscription-mediated amplificationHepacivirusAlpha interferonHepacivirusInterferon alpha-2GastroenterologyAntiviral AgentsSensitivity and Specificityantiviral therapy EVR HCV chronic hepatitis HCV-RNA RT-PCR TMAPolyethylene Glycolschemistry.chemical_compoundInterferonPredictive Value of TestsVirologyInternal medicineRibavirinmedicineHumansRetrospective StudiesSettore MED/12 - GastroenterologiaHepatologybiologybusiness.industryReverse Transcriptase Polymerase Chain ReactionRibavirinInterferon-alphaNucleic acid amplification techniqueHepatitis C Chronicbiology.organism_classificationVirologydigestive system diseasesRecombinant ProteinsInfectious DiseasesReal-time polymerase chain reactionTreatment OutcomechemistryRNA ViralDrug Therapy CombinationFemalebusinessNucleic Acid Amplification Techniquesmedicine.drug
researchProduct

Influence of HMB Supplementation and Resistance Training on Cytokine Response to Resistance Exercise

2014

The purpose of this study was to determine the effects of a multinutritional supplement including amino acids, β-hydroxy-β-methylbutyrate (HMB), and carbohydrates on cytokine responses to resistance exercise and training.Seventeen healthy, college-aged men were randomly assigned to a Muscle Armor™ (MA; Abbott Nutrition, Columbus, OH) or placebo supplement group and 12 weeks of resistance training. An acute resistance exercise protocol was administered at 0, 6, and 12 weeks of training. Venous blood samples at pre-, immediately post-, and 30-minutes postexercise were analyzed via bead multiplex immunoassay for 17 cytokines.After 12 weeks of training, the MA group exhibited decreased interfer…

Malemedicine.medical_specialtyStrength trainingmedicine.medical_treatmentInterleukin-1betaMedicine (miscellaneous)Immune functionGranulocytePlaceboBody Mass IndexInterferon-gammaYoung AdultDouble-Blind MethodMuscle damageInternal medicineMyokineMyokinemedicineDietary CarbohydratesValeratesHumansMicronutrientsAmino Acidsta315Chemokine CCL4Immune function; Muscle damage; Myokine; Nutrition; Strength trainingChemokine CCL2NutritionNutrition and DieteticsInterleukin-13business.industryInterleukin-6MonocyteBody WeightInterleukin-8InterleukinResistance TrainingVenous bloodHealthy VolunteersInterleukin-10Cytokinemedicine.anatomical_structureEndocrinologyNutrition AssessmentImmunologyDietary SupplementsCytokinesStrength trainingbusiness
researchProduct

Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: a randomised non-inf…

2015

AbstractZostavax® is a live, attenuated varicella zoster virus (VZV) vaccine developed specifically for the prevention of HZ and PHN in individuals aged ≥50 years. During the clinical development of Zostavax, which was mainly in the US, the vaccine was administrated by the subcutaneous (SC) route. In Europe, many healthcare professionals prefer administering vaccines by the intramuscular (IM) route. This was an open-label, randomised trial conducted in 354 subjects aged ≥50 years. The primary objectives were to demonstrate that IM administration is both non-inferior to SC administration in terms of 4-week post-vaccination geometric mean titres (GMTs), and elicits an acceptable geometric mea…

Malemedicine.medical_specialtySub-cutaneous administration routeEnzyme-Linked Immunospot AssayHerpesvirus 3 HumanInjections SubcutaneousVaricella zoster virus vaccinePainmedicine.disease_causeAntibodies ViralVaccines AttenuatedHerpes ZosterInjections Intramuscularlaw.inventionShinglesInterferon-gammaRandomized controlled triallawImmunology and Microbiology(all)Internal medicinemedicineEdemaHerpes Zoster VaccineHumansAdverse effectAgedRandomised controlled trialAged 80 and overAttenuated vaccineIntention-to-treat analysisGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryELISPOTImmunogenicityVaccinationPublic Health Environmental and Occupational HealthVaricella zoster virusIntramuscular administration routeMiddle Agedmedicine.diseaseveterinary(all)Infectious DiseasesErythemaImmunologyMolecular MedicineFemalebusinessShinglesVaccine
researchProduct

Comparative responses to three different types of interferon-α in patients with chronic hepatitis C

1999

We investigated the efficacy and tolerability of three different types of interferon-alpha, administered with the same schedule to naive patients with chronic hepatitis C. One hundred and seven patients with histologically proven chronic hepatitis C were enrolled during a period of three years and randomly divided into three groups, to receive (a) leukocyte-interferon-alpha, 6 MU three times a week for 4 months, followed by 3 MU three times a week for 8 months (Group I); (b) recombinant-IFN-alpha-2a, with the same schedule (Group II); and (c) lymphoblastoid-IFN-alpha-N1, with the same schedule (Group III). All patients were followed-up for 6 months to evaluate the long-term response. The 'C…

Malemedicine.medical_specialtyTime FactorsCirrhosisAlpha interferonGastroenterologyStatistics Nonparametriclaw.inventionRandomized controlled triallawInternal medicinemedicineHumansAdverse effectAgedAnalysis of Variancebusiness.industryBiopsy NeedleRemission InductionInterferon-alphaGamma globulinGeneral MedicineHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant ProteinsLiverTolerabilityInterferon Type IImmunologyFemaleAnalysis of variancebusiness
researchProduct

Antiproliferative effect of interferons on human prostate carcinoma cell lines.

1989

The effect of purified human fibroblast beta-interferon (B-IFN) and recombinant alpha-2b-interferon (A-IFN) on cell proliferation was investigated in two human prostate carcinoma cell lines, named PC-3 and DU-145. Both cell lines respond to the antiproliferative action of interferon, B-IFN being more effective than A-IFN. PC-3 is more sensitive than DU-145 cell line, showing 95% inhibition of cell proliferation at the highest concentration of B-IFN. As interferons, besides reducing cell growth, are able to modify steroid receptor content in different hormone-sensitive human tumours, our results may be of some relevance as these drugs might be used to regulate both cell proliferation and hor…

Malemedicine.medical_specialtyUrologymedicine.medical_treatmentBiologyInterferon alpha-2law.inventionSteroidCell LineProstate cancerlawInterferonInternal medicinemedicineTumor Cells CulturedHumansReceptorFibroblastCell growthInterferon-alphaProstatic Neoplasmsmedicine.diseaseRecombinant ProteinsEndocrinologymedicine.anatomical_structureCell cultureInterferon Type ICancer researchRecombinant DNACell Divisionmedicine.drugUrological research
researchProduct